Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Malignant Melanoma

  Free Subscription


24.08.2020

1 Am J Dermatopathol
1 Am J Ophthalmol
1 Biochem Biophys Res Commun
1 BMC Cancer
2 Clin Cancer Res
1 Eur J Dermatol
1 Int J Cancer
2 J Immunother
1 J Invest Dermatol
2 Melanoma Res


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Dermatopathol

  1. RAMOS-RODRIGUEZ C, Garcia-Arpa M, Relea-Calatayud MF, Gonzalez-Lopez L, et al
    Metastatic Melanoma Negative for 5 Melanocytic Markers, Complete Regressed Primary Cutaneous Melanoma, and Melanoma-Associated Leukoderma in the Same Patient.
    Am J Dermatopathol. 2020 Aug 17. doi: 10.1097/DAD.0000000000001774.
    PubMed         Abstract available


    Am J Ophthalmol

  2. KLOFAS LK, Bogan CM, Coogan A, Schultenover SJ, et al
    Instrument gauge and type in uveal melanoma fine needle biopsy: implications for diagnostic yield and molecular prognostication.
    Am J Ophthalmol. 2020 Aug 17. pii: S0002-9394(20)30440.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  3. LACARIA L, Lange JR, Goldmann WH, Rico F, et al
    Corrigendum to "alphavbeta3 integrin expression increases elasticity in human melanoma cells" [Biochem. Biophys. Res. Commun. 525 (2020)].
    Biochem Biophys Res Commun. 2020 Aug 12. pii: S0006-291X(20)31546.
    PubMed        


    BMC Cancer

  4. WEIGERT V, Jost T, Hecht M, Knippertz I, et al
    PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts.
    BMC Cancer. 2020;20:775.
    PubMed         Abstract available


    Clin Cancer Res

  5. MIDDLETON MR, McAlpine C, Woodcock VK, Corrie P, et al
    Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated anti-tumor immune responses in patients with metastatic melanoma.
    Clin Cancer Res. 2020 Aug 18. pii: 1078-0432.CCR-20-1247.
    PubMed         Abstract available

  6. MARUSAK C, Thakur V, Li Y, Freitas JT, et al
    Targeting Extracellular Matrix Remodeling restores BRAF Inhibitor Sensitivity in BRAFi Resistant Melanoma.
    Clin Cancer Res. 2020 Aug 20. pii: 1078-0432.CCR-19-2773.
    PubMed         Abstract available


    Eur J Dermatol

  7. DALLE S, Varey E, Nguyen JM, Dupuy A, et al
    Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database.
    Eur J Dermatol. 2020 Aug 19. pii: ejd.2020.3848. doi: 10.1684/ejd.2020.3848.
    PubMed         Abstract available


    Int J Cancer

  8. SATO M, Onuma K, Domon M, Hasegawa S, et al
    Loss of the cystine/glutamate antiporter in melanoma abrogates tumor metastasis and dramatically increases survival rates of mice.
    Int J Cancer. 2020 Aug 20. doi: 10.1002/ijc.33262.
    PubMed         Abstract available


    J Immunother

  9. VAN ZEIJL MCT, Haanen JBAG, Wouters MWJM, de Wreede LC, et al
    Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study.
    J Immunother. 2020 Aug 14. doi: 10.1097/CJI.0000000000000334.
    PubMed         Abstract available

  10. COMITO F, Leslie I, Boos L, Furness A, et al
    Oligoprogression After Checkpoint Inhibition in Metastatic Melanoma Treated With Locoregional Therapy: A Single-center Retrospective Analysis.
    J Immunother. 2020 Aug 11. doi: 10.1097/CJI.0000000000000333.
    PubMed         Abstract available


    J Invest Dermatol

  11. CORNELIUS LA
    The Melanoma JID Connector Collection: An Introduction.
    J Invest Dermatol. 2020;140:1690.
    PubMed        


    Melanoma Res

  12. DIVINCENZO MJ, Latchana N, Abrams Z, Moufawad M, et al
    Tissue microRNA expression profiling in hepatic and pulmonary metastatic melanoma.
    Melanoma Res. 2020 Aug 13. doi: 10.1097/CMR.0000000000000692.
    PubMed         Abstract available

  13. WILSON MA, Zhong J, Johannet P, Lee Y, et al
    Preliminary analysis of distinct clinical and biologic features of bone metastases in melanoma.
    Melanoma Res. 2020 Aug 13. doi: 10.1097/CMR.0000000000000691.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: